文献速递糖尿病

波利尼西亚与法国本土人群活检证实的糖尿病肾病差异:一项回顾性队列研究

Differences in biopsy-proven diabetic kidney disease in individuals from Polynesia vs mainland France: a retrospective cohort study.
PubMed 文献 · Diabetologia · 2025-06-27

该回顾性队列研究比较了法属波利尼西亚(92例)与法国本土(63例)2型糖尿病且活检证实糖尿病肾病患者的特征与结局。波利尼西亚患者活检时更年轻(56.5 vs 66.9岁,p<0.001)、尿蛋白/肌酐比更高(792 vs 452 mg/mmol,p<0.001),肾脏病理学会(RPS)分级更严重(p<0.001)。校正尿蛋白/肌酐比、eGFR、BMI和基线年龄后,波利尼西亚患者进展至终末期肾病的风险更高(HR 2.45 [95% CI 1.23, 4.88])。

要点

  • 波利尼西亚患者活检时更年轻(56.5 vs 66.9岁,p<0.001)且尿蛋白/肌酐比更高(792 vs 452 mg/mmol,p<0.001)。
  • 波利尼西亚患者RPS分级更严重(p<0.001),中位肾脏生存期更短(1.59 vs 6.06年)。
  • 校正混杂因素后,波利尼西亚患者终末期肾病风险更高(HR 2.45 [95% CI 1.23, 4.88])。

核心结论

  • 法属波利尼西亚人群的糖尿病肾病进展较法国本土人群更严重且发病年龄更早。
  • 不同种族人群在糖尿病肾病的临床、组织学及预测结局方面存在显著差异。

研究设计与样本

  • 回顾性队列研究,纳入法属波利尼西亚92例和法国本土63例2型糖尿病且活检证实糖尿病肾病的患者。
  • 比较两组患者的基线特征、肾脏生存(以死亡为竞争风险)、RPS评分及患者生存。

主要发现

  • 活检时,波利尼西亚患者较法国本土患者更年轻(56.5 vs 66.9岁,p<0.001),尿蛋白/肌酐比更高(792 vs 452 mg/mmol,p<0.001),糖尿病病程更短(8.7 vs 11.1年,p=0.008),抗蛋白尿治疗和eGFR相似。
  • 波利尼西亚患者RPS分级更严重(p<0.001)。
  • 从活检至需要替代治疗的肾衰竭中位时间:波利尼西亚人群1.59年,法国本土人群6.06年(以死亡为竞争风险)。
  • 校正uPCR、eGFR、BMI和基线年龄后,波利尼西亚患者终末期肾病风险更高(HR 2.45 [95% CI 1.23, 4.88])。
  • 在多变量模型中,波利尼西亚 origin、较高uPCR、较低eGFR、更严重RPS分级及慢性血管病变的存在均与较差的肾脏生存独立相关;RPS分级与肾脏生存的关联在波利尼西亚患者中更强(交互作用p=0.048),而较高uPCR与肾脏生存的关联在法国本土患者中更强(交互作用p<0.001)。

关键数值与推荐

  • RPS分级更严重(p<0.001)。
  • 校正后终末期肾病风险HR 2.45(95% CI 1.23, 4.88)。
  • RPS分级与肾脏生存的交互作用p=0.048;uPCR与肾脏生存的交互作用p<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Māori, a Polynesian population, have an earlier age of onset of type 2 diabetes and higher risk of diabetes-related complications compared with New Zealanders of European descent, and an increased incident rate ratio for end stage kidney disease. No data are available regarding the evolutive characteristics of diabetic kidney disease (DKD) in individuals living in French Polynesia. METHODS: We aimed to compare the retrospectively collected characteristics and outcomes of 92 and 63 individuals from French Polynesia and mainland France, respectively, presenting type 2 diabetes and biopsy-confirmed DKD, focusing on kidney survival, analysis of the Renal Pathology Society (RPS) score and participant survival. RESULTS: At the time of biopsy, Polynesian participants were younger (56.5 vs 66.9 years, p<0.001) and had a higher urinary protein/creatinine ratio (uPCR) (792 vs 452 mg/mmol, p<0.001), despite similar anti-proteinuria treatments and eGFR, and shorter time since diabetes diagnosis (8.7 vs 11.1 years, p=0.008). Polynesian participants had a more severe RPS classification (p<0.001). Median time from biopsy to kidney failure with replacement therapy was 1.59 years in the Polynesian population and 6.06 years in the mainland French population, accounting for death as a competing risk. Polynesian participants were at a higher risk of end stage kidney disease after adjustment for uPCR, eGFR, BMI and age at baseline (HR 2.45 [95% CI 1.23, 4.88]). In a clinical and histological reduced multivariable model, Polynesian origin, higher uPCR, lower eGFR, more severe RPS classification and presence of chronic vascular lesions were all independently associated with poorer kidney survival. The RPS classification was more strongly associated with kidney survival in participants from Polynesia (p value for interaction, 0.048), while a higher uPCR was more strongly associated with kidney survival in participants from mainland France (p value for interaction, <0.001). Older age and Polynesian origin were also independent risk factors for death. CONCLUSIONS/INTERPRETATION: Starting at an earlier age, the evolutive course of DKD is also more severe in individuals from French Polynesia than from mainland Western Europe. Strong differences in clinical, histological and predictive outcomes of diabetic nephropathy were found in these different ethnic groups.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Michel M, Flahault A, Coliche V, et al. Differences in biopsy-proven diabetic kidney disease in individuals from Polynesia vs mainland France: a retrospective cohort study. Diabetologia. 2025. PMID: 40579640. doi:10.1007/s00125-025-06471-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。